Trigeminal neuralgia

Cheshire, William P.

doi:10.1007/s11916-007-0025-7

Cited by 13 publications

(5 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The second group consisted of complications that were non–life‐threatening or minor (mild) and/or not directly related to FOE, such as facial pain, cheek bleeding, and fever not attributable to meningitis. Recognizing that facial pain can be a very disturbing condition (Cheshire, 2007), only mild neuralgic pain that was well controlled with medication was included in the second group. In this sense, although potentially quite disturbing for patients, facial neuralgia was included among the minor, transient complications due to the lack of vital compromise.…”

Section: Methodsmentioning

confidence: 99%

Morbidity associated with the use of foramen ovale electrodes

Pastor¹,

Sola²,

Hernando‐Requejo³

et al. 2007

Epilepsia

View full text Add to dashboard Cite

SUMMARYPurpose: The identification of the epileptic zone in patients with mesial temporal lobe epilepsy sometimes requires intracranial recordings, for example, with foramen ovale electrodes (FOE). This paper reviews and analyzes the resulting complications in a series of patients studied with bilateral FOE for presurgical evaluation. Prior to performing surgery for refractory mesial temporal lobe epilepsy (MTLE), the epileptogenic zone must be correctly identified (Lüders and Awad, 1991;Engel et al., 1997;Sola, 1997). While noninvasive tests are usually adequate, invasive video-EEG monitoring methods are sometimes required (Boon and Williamson, 1989;Wieser and Williamson, 1993). These can include the use of foramen

show abstract

Section: Methodsmentioning

confidence: 99%

Morbidity associated with the use of foramen ovale electrodes

Pastor¹,

Sola²,

Hernando‐Requejo³

et al. 2007

Epilepsia

View full text Add to dashboard Cite

show abstract

“…In comparison, carbamazepine may only be effective in 39 % of SUNCT cases and 20 % of SUNA cases [30]. As such, a trial of carbamazepine may help in differentiating TN from SUNCT or SUNA [31] with maintenance doses typically between 300 and 800 mg/day. SUNCT and SUNA are often considered to be refractory to treatment, but there is mounting evidence that they may respond to a number of drugs including lamotrigine (68 % effective in SUNCT, 25 % effective in SUNA), topiramate (52 % effective in SUNCT, 0 % effective in SUNA) and gabapentin (45 % effective in SUNCT, 60 % effective in SUNA) [30].…”

Section: Response To Medical or Surgical Treatmentmentioning

confidence: 99%

Tic Versus TAC: Differentiating the Neuralgias (Trigeminal Neuralgia) from the Cephalalgias (SUNCT and SUNA)

VanderPluym

Richer

2014

Curr Pain Headache Rep

View full text Add to dashboard Cite

Trigeminal neuralgia, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks with autonomic symptoms (SUNA) are classified as distinct disorders in the International Classification of Headache Disorders 3 beta (ICHD-3 beta). SUNCT and SUNA are primary headache disorders included among the trigeminal autonomic cephalalgias. Trigeminal neuralgia is classified under painful cranial neuropathies and other facial pains. The classification criteria of these conditions overlap significantly which could lead to misdiagnosis. The reported overlap among these conditions has called into question whether they should be considered distinct entities or rather a continuum of the same disorder. This review explores the known overlap and how other features not included in the ICHD-3 beta criteria may better differentiate the "Tics" (trigeminal neuralgia) from the "TACs" (SUNCT and SUNA).

show abstract

“…Indisputably, carbamazepine (400–1,200 mg/day) and oxcarbazepine (900–1,800 mg/ day) represent the first-choice TN medical treatment ( 22 ). However, even though they are effective in 80% of patients, their clinical benefit may decrease over time and their use is frequently associated to significant side effects (drowsiness, nausea, dizziness, ataxia, hyponatremia, and liver enzymes elevation) ( 23 ). Neurosurgical procedures (such as microvascular decompression and radio-surgical treatment)—considered for refractory cases—induce clinical benefit in almost 60–90% of cases but may be followed by complications or pain recurrence ( 23 , 24 ).…”

Section: Results: Bont In Neuropathic Painmentioning

confidence: 99%

Botulinum Neurotoxin for the Treatment of Neuropathic Pain

2020

View full text Add to dashboard Cite

Botulinum neurotoxin is widely used for the treatment of central and peripherical neurological conditions. Initially used to treat strabismus, over the years its use has been expanded also to spasticity and other neurological disorders. This review summarizes the evidence from the published literature regarding its effect on neuropathic pain. Almost all investigations were performed using onabotulinum toxin type A (BoNT/A). Most studies provided positive results, even though toxin formulation, dose, dilution, injection techniques, and sites are heterogeneous across studies. Future larger, high-quality, specifically designed clinical trials are warranted to confirm botulinum neurotoxin efficacy in neuropathic pain.

show abstract

Trigeminal neuralgia

Cited by 13 publications

References 50 publications

Morbidity associated with the use of foramen ovale electrodes

Morbidity associated with the use of foramen ovale electrodes

Tic Versus TAC: Differentiating the Neuralgias (Trigeminal Neuralgia) from the Cephalalgias (SUNCT and SUNA)

Botulinum Neurotoxin for the Treatment of Neuropathic Pain

Contact Info

Product

Resources

About